for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Limited

PFIZ.NS

Latest Trade

3,267.85INR

Change

23.35(+0.72%)

Volume

55,678

Today's Range

3,225.00

 - 

3,399.80

52 Week Range

2,501.00

 - 

3,473.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
3,244.50
Open
3,250.00
Volume
55,678
3M AVG Volume
0.42
Today's High
3,399.80
Today's Low
3,225.00
52 Week High
3,473.00
52 Week Low
2,501.00
Shares Out (MIL)
45.75
Market Cap (MIL)
149,496.70
Forward P/E
31.17
Dividend (Yield %)
0.69

Latest Developments

More

India's Pfizer Ltd March-qtr Profit Rises

EMA Says CHMP Recommends Granting A Conditional Marketing Authorisation For Waylivra

India's Pfizer Dec-Qtr Profit Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Limited

Pfizer Limited is an India-based pharmaceutical company. The Company has a portfolio of approximately 140 products across over 15 therapeutic areas. The Company is engaged in manufacturing, marketing, trading and exporting pharmaceutical products. The Company offers a range of products for Anti-Allergic, Anti-Diabetic, Antihistamine, Anti-Infectives, Cardiovascular, Dermatology, Erectile Dysfunction, gastrointestinal (GI), Multivitamins, Pain/Inflammation+GI, Respiratory, Urology and Vitamin/Minerals, among others. Its products include LC-OD Plus, Bidiab, Voglibose, Histizer, Isokin, Jetex Suspension, Nebasulf Ointment, Trulimax, Combantrin A, Newsta, Selsun, Agarol, Oxileptin, Ponstan, Daxid, Tricorex, Citrosoda and Cognisules, among others. The Company has its own manufacturing facility at Thane and Goa. The Company has various independent contract/third party manufacturers based across the country. The Company sells its products through independent distributors primarily in India.

Industry

Major Drugs

Contact Info

Pfizer Centre, 5, Patel Estate

Off S.V. Road, Jogeshwari (W)

+91.22.66932000

http://www.pfizerindia.com/

Executive Leadership

Rajendra A. Shah

Independent Non-Executive Chairman of the Board

Milind Patil

Executive Director - Finance, Director

Prajeet Nair

Compliance Officer, Company Secretary

S. Sridhar

Managing Director, Whole Time Director

Vivek Dhariwal

Executive Director - Technical Operations, Whole-time Director

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

19.7K

2018

19.7K

2019

20.8K

2020(E)

23.5K
EPS (INR)

2017

53.600

2018

78.700

2019

93.780

2020(E)

104.842
Price To Earnings (TTM)
33.22
Price To Sales (TTM)
7.07
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
28.31
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

REFILE-BRIEF-India's Pfizer Ltd Says News On Stopping Ops In Chennai, Aurangabad Units Unrelated To Co

* CLARIFIES ON NEWS ARTICLE ABOUT PFIZER TO STOP MANUFACTURING OPERATIONS IN CHENNAI, AURANGABAD UNITS

BRIEF-India's Pfizer March Qtr Profit Rises

* MARCH QUARTER NET PROFIT 1.05 BILLION RUPEES VERSUS PROFIT OF 680.4 MILLION RUPEES YEAR AGO

BRIEF-Pfizer Ltd Says Pfizer Inc Has Not Yet Made Decision w.r.t Strategic Alternatives For Global Consumer Healthcare Business​

* PFIZER INC. TOLD CO'S BOARD THAT NO DECISION HAS YET BEEN MADE WITH RESPECT TO ANY STRATEGIC ALTERNATIVES FOR GLOBAL CONSUMER HEALTHCARE BUSINESS

BRIEF-Pfizer Says Ravi Prakash Bhagavathula Resigned As CFO

* SAYS RAVI PRAKASH BHAGAVATHULA RESIGNED AS CFO Source text - http://bit.ly/2CxVrV6 Further company coverage:

BRIEF-India's Pfizer Dec-Qtr Profit Rises

* DEC QUARTER NET PROFIT 872.4 MILLION RUPEES VERSUS PROFIT OF 623.7 MILLION RUPEES YEAR AGO

BRIEF-Pfizer Sept-qtr profit down about 12 pct

* Sept quarter net profit 1.11 billion rupees versus profit of 1.26 billion rupees last year

BRIEF-India's Pfizer Ltd signs deal to buy Neksium brand from AstraZeneca AB, Sweden

* Says entered into an acquisition agreement with AstraZeneca AB, Sweden

BRIEF-Pfizer Ltd says news on USFDA observations for Hospira Vizag unit does not relate to Pfizer, India

* Clarifies on news item "Pfizer's Hospira Vizag unit receives 11 observation from US FDA"

BRIEF-Pfizer Ltd Dec-qtr profit up about 4 pct

* Dec quarter total income from operations 5.10 billion rupees

BRIEF-Pfizer Ltd Sept-qtr profit up about 52 pct

* Sept quarter total income from operations 5.58 billion rupees

BRIEF-Pfizer Ltd completes sale of 4 products to Piramal Enterprises

* Completion of transaction of the sale of four products to piramal enterprises limited Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up